Phase II trial of vindesine in patients with germ-cell tumors

T. F. Reynolds, D. Vugrin, E. Cvitkovic, R. J. Gralla, C. W. Young, R. B. Golbey

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.

Original languageEnglish (US)
Pages (from-to)1399-1401
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number8
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of vindesine in patients with germ-cell tumors'. Together they form a unique fingerprint.

  • Cite this

    Reynolds, T. F., Vugrin, D., Cvitkovic, E., Gralla, R. J., Young, C. W., & Golbey, R. B. (1979). Phase II trial of vindesine in patients with germ-cell tumors. Cancer Treatment Reports, 63(8), 1399-1401.